Revolution Medicines, Inc. Earnings Per Share, Basic and Diluted
Revolution Medicines, Inc. (RVMD) reported Earnings Per Share, Basic and Diluted of -$0.78 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-09.
Discontinued › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-09
- Revolution Medicines, Inc. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.78.
- Revolution Medicines, Inc. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.71.
- Revolution Medicines, Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.72.
- Revolution Medicines, Inc. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.60.
- Revolution Medicines, Inc. earnings per share, basic and diluted for fiscal 2021 was -$2.57.
- Revolution Medicines, Inc. earnings per share, basic and diluted for fiscal 2020 was -$2.01.
- Revolution Medicines, Inc. earnings per share, basic and diluted for fiscal 2019 was -$22.33.
- Revolution Medicines, Inc. earnings per share, basic and diluted for fiscal 2018 was -$21.24.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$0.78 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | -$0.71 derived: net income ÷ weighted average shares · filed 2024-02-26 | -$1.43 derived: net income ÷ weighted average shares · filed 2024-02-26 | -$2.04 derived: net income ÷ weighted average shares · filed 2024-02-26 | -$2.57 10-K · filed 2022-02-28 |
| 2021-09-30 | -$0.72 10-Q · filed 2021-11-10 | -$1.32 derived: net income ÷ weighted average shares · filed 2021-11-10 | -$1.85 10-Q · filed 2021-11-10 | -$2.38 derived: net income ÷ weighted average shares · filed 2023-02-27 |
| 2021-06-30 | -$0.60 10-Q · filed 2021-08-11 | -$1.13 10-Q · filed 2021-08-11 | -$1.65 derived: net income ÷ weighted average shares · filed 2023-02-27 | -$2.08 derived: net income ÷ weighted average shares · filed 2023-02-27 |
| 2021-03-31 | -$0.53 10-Q · filed 2022-05-09 | -$1.04 derived: net income ÷ weighted average shares · filed 2023-02-27 | -$1.47 derived: net income ÷ weighted average shares · filed 2023-02-27 | -$1.93 derived: net income ÷ weighted average shares · filed 2023-02-27 |
| 2020-12-31 | -$0.52 10-K · filed 2021-03-02 | -$0.94 derived: net income ÷ weighted average shares · filed 2023-02-27 | -$1.40 derived: net income ÷ weighted average shares · filed 2023-02-27 | -$2.01 10-K · filed 2022-02-28 |
| 2020-09-30 | -$0.42 10-Q · filed 2021-11-10 | -$0.88 derived: net income ÷ weighted average shares · filed 2021-11-10 | -$1.49 10-Q · filed 2021-11-10 | -$2.44 derived: net income ÷ weighted average shares · filed 2022-02-28 |
| 2020-06-30 | -$0.46 10-Q · filed 2021-08-11 | -$1.11 10-Q · filed 2021-08-11 | -$2.24 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$3.62 derived: net income ÷ weighted average shares · filed 2022-02-28 |
| 2020-03-31 | -$0.74 10-Q · filed 2021-05-10 | -$2.52 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$4.94 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$7.51 derived: net income ÷ weighted average shares · filed 2022-02-28 |
| 2019-12-31 | -$6.48 10-K · filed 2021-03-02 | -$12.54 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$17.44 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$22.33 10-K · filed 2022-02-28 |
| 2019-09-30 | -$6.08 10-K · filed 2021-03-02 | -$10.95 derived: net income ÷ weighted average shares · filed 2020-11-12 | -$15.81 10-Q · filed 2020-11-12 | |
| 2019-06-30 | -$4.85 10-K · filed 2021-03-02 | -$9.69 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | -$4.84 10-K · filed 2021-03-02 | |||
| 2018-12-31 | -$21.24 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |